Cost-effectiveness of psychotropic polypharmacy in routine schizophrenia care. Results of the ELAN prospective observational trial

Statistical associations between type of psychopharmacological treatment on the one hand and the net monetary benefit on the other suggest that antipsychotic monotherapy is related to lower costs and better outcomes in comparison to any type of polypharmaceutical treatment. Further studies with more rigorous study designs are necessary to further elucidate the direction of causality in the detected associations.